NDAL Mfg's honey nasal sprays had manufacturing-rule violations, microbial contamination, and lacked FDA approval as new drugs.
What happened
FDA inspected NDAL Mfg's Monterey, California facility from September 8 to 20, 2021, and reviewed the company's website and product labels. FDA found significant CGMP (current good manufacturing practice, the rules for drug manufacturing) violations, an inadequate investigation of microbial contamination in recalled ManukaGuard Allercleanse nasal spray lot 2010045, and inadequate stability data for three-year expiry claims. FDA also found the honey nasal sprays and sinus cleanser were unapproved new drugs because of claims on labels and the website.
What FDA found
NDAL had no quality unit and lacked procedures and specifications to ensure its contract-made drug products met quality standards.
21 CFR 211.22NDAL did not thoroughly investigate microbial contamination in ManukaGuard Allercleanse nasal spray lot 2010045 or check whether other batches or products were affected.
21 CFR 211.192NDAL lacked adequate stability data to support the three-year expiration dates on its over-the-counter drug products.
21 CFR 211.137(a)NDAL sold honey nasal sprays and a sinus cleanser as unapproved new drugs because their labels and website claimed they treated or prevented disease or affected body function, without FDA-approved applications.
FD&C Act section 505(a), 21 U.S.C. 355(a)NDAL labeled some ManukaGuard honey products as dietary supplements even though the label told users to take them under the tongue; only products intended for ingestion can be dietary supplements.
FD&C Act section 201(ff)
What FDA wants
FDA tells NDAL to correct the cited CGMP and unapproved-drug violations, respond in writing within 15 working days with actions taken, and notify FDA before resuming U.S. drug production.
Who should pay attention
- brands that buy nasal sprays or sinus products from contract manufacturers
- companies making honey-based products with drug-like claims
- quality teams that oversee contract manufacturers and stability testing
This is a summary. Read the original letter on fda.gov.